World-leader in the field of complex weapon systems, MBDA is the only European group capable of designing and manufacturing complex weapons to meet the full range of operational requirements of the three armed forces (land, sea and air). MBDA is owned by Airbus (37.5%), BAE Systems (37.5%) and Leonardo (25%).
French industrial SME created in 2003, Ouvry company specializes in the creation, engineering, production and maintenance of personal body and respiratory protection systems, and decontamination against chemical, biological, radiological or nuclear threats (CBRN). It therefore provides innovative products designed and developed to meet especially the needs of military and special security forces.
Ouvry designs and manufactures its products with a French and European supply chain: more than 200,000 coveralls manufactured for more than 800 customers in more than 55 countries.
24 Avenue Joannès Masset
ZA Gorge de Loup Bâtiment E EST
69009 Lyon
SERB is a growing specialty pharmaceutical company dedicated to treating patients with critical conditions, focusing on emergency care and rare diseases. SERB has one of the most comprehensive, wide-ranging antidote portfolios in the world, covering CBRN risks such as nerve agent, cyanide and heavy metal poisoning. Our medical countermeasures are mainly manufactured within Europe and exported to over 100 countries. SERB is a longstanding partner for hospitals, health authorities, governmental and non-governmental agencies, national and regional stockpiles, and therapeutic area experts.
Today SERB is fully integrated company with the experience and capabilities to acquire, develop and manufacture our medicines to the highest standards, and make them available worldwide through our secure supply chain.
SERB is one of the few companies in the world manufacturing polyclonal antibodies at a commercial scale and to rigorous enough, quality standards to satisfy regulators in all territories. For over 20 years, we’ve used this technology to produce two commercially available products. More recently, we have begun to use this platform to develop novel biologic therapies against a wide range of toxins, drugs, and viruses for use around the world.
1
3
3
3
2
1
115
15
7
1
1
6
5
9
3
3
5
7
4
1
2
1
2
3
5
4
2
3
7
17
CZE
ENG
